文献速递贫血与红细胞疾病

新型强效口服生物利用度LSD1抑制剂在镰状细胞病小鼠模型中诱导胎儿血红蛋白合成

Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model.
PubMed 文献 · Blood · 2025-01-01

研究利用结构辅助药物设计开发了新型可逆LSD1抑制剂,在体外诱导红系细胞γ-珠蛋白表达,在镰状细胞病小鼠模型中口服给药可显著升高胎儿血红蛋白并减轻多种疾病病理特征,与BRD4降解剂BD-9136联用可挽救LSD1抑制剂伴随的红系向髓系谱系转化。

要点

  • 新型可逆LSD1抑制剂在体外诱导红系细胞强效γ-珠蛋白表达。
  • 镰状细胞病小鼠口服新型LSD1抑制剂后胎儿血红蛋白显著升高并减轻多种病理特征。
  • LSD1抑制剂与BRD4降解剂BD-9136联用可抑制RUNX1和PU.1诱导,挽救红系向髓系转化。

核心结论

  • 新一代LSD1抑制剂可有效诱导胎儿血红蛋白水平、减轻镰状细胞病病理表现,且在镰状细胞病小鼠中口服给药耐受良好。
  • 作者预期这些或相关二元化合物联合应用为治疗镰状细胞病和β-地中海贫血重型提供新的治疗可能。

研究设计与样本

  • 研究采用结构辅助药物设计开发新型可逆LSD1抑制剂,并在体外及镰状细胞病小鼠模型中评价其诱导胎儿血红蛋白及改善病理的作用。

主要发现

  • 新型可逆LSD1抑制剂在体外导致红系细胞强效γ-珠蛋白表达。
  • 在镰状细胞病小鼠模型中,口服这些新型抑制剂导致胎儿血红蛋白显著升高并减轻镰状细胞病常见的多种疾病病理特征。
  • LSD1抑制剂与BRD4降解剂BD-9136联合处理可抑制RUNX1和PU.1的诱导,从而挽救造血中伴随LSD1抑制剂的红系向髓系谱系转化。
  • 数据表明新一代LSD1抑制剂可有效诱导胎儿血红蛋白水平、减轻镰状细胞病病理,且在镰状细胞病小鼠中口服给药耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small molecules that inhibit LSD1 (lysine-specific demethylase 1, KDM1A) have been shown to induce abundant fetal hemoglobin (HbF) levels in red blood cells both in vitro and in vivo, therefore potentially serving as potent and cost-effective therapeutics to treat the β-globinopathies, sickle cell disease (SCD), and β-thalassemia major (TM). However, most LSD1 inhibitors (LSD1is) that induce HbF in vivo are covalent and irreversible, which leads to adverse effects. In this study, we utilized structure-aided drug design to develop potent new reversible LSD1is, leading to robust γ-globin expression in vitro. Moreover, in a mouse model of SCD, oral administration of these novel inhibitors leads to significant HbF elevation and alleviation of multiple features of disease pathology that are the usual consequences of SCD. In addition, we discovered that combined treatment of an LSD1i with a BRD4 degrader (BD-9136) represses the induction of RUNX1 and PU.1, thereby rescuing the erythroid to myeloid lineage conversion that accompanies LSD1is in hematopoiesis. The data indicate that this new generation of LSD1is can effectively induce HbF levels, reduce SCD pathologies, and are well tolerated by oral administration in SCD mice. We anticipate that the combination of these or related binary compounds offer exciting new therapeutic possibilities for treating SCD and TM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang Y, Yu L, Deng K, et al. Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model. Blood. 2025. PMID: 40332031. doi:10.1182/blood.2024028006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。